Angiotensin II (ANG II) plays critical roles in modulation of circulatory homeostasis and activation of innate and adaptive immunity and has also been implicated in several mouse models of autoimmune disease. However, how ANG II regulates macrophages and is involved in development of experimental autoimmune myocarditis (EAM) remains unclear. Therefore, the present study aimed to address the above question and explore possible mechanisms. EAM was induced in BALB/c mice. ANG II was quantitated by ELISA and hematoxylin and eosin staining was employed to analyze pathological changes and macrophage infiltration. The chemotactic ability of ANG II was assessed by using a Transwell system. It was found that ANG II is up-regulated in serum and heart tissues of mice with EAM and that ANG II significantly drives monocyte/macrophage infiltration through the C-C chemokine receptor 2/5 (CCR2/5) axis. CCR2/5 antagonists and ANG II receptor inhibitor could all abrogate monocyte/macrophage infiltration and ameliorate development of EAM. Our results have firstly identified a novel function of ANG II: that it is a critical chemokine for monocyte/macrophage recruitment. Furthermore, our results indicate that ANG II is a potential candidate for treatment of inflammatory diseases.
Inflammatory dilated cardiomyopathy, one of the leading causes of severe heart failure, is generally caused by coxsackievirus B3-triggered myocarditis (1, 2) . EAM is characterized by inflammatory cell infiltration, necrosis of cardiac myocytes and subsequent deterioration in cardiac function (3, 4) . Published data have implicated monocytes/macrophages as the most prominent population of leucocytes that infiltrate heart tissue affected by EAM (5) . Such infiltrated monocytes/macrophages can reprogram their functional phenotypes and become involved in initiation and resolution of inflammation and fibrosis as well as cardiac function remodeling following changes in their microenvironment (6, 7) . Furthermore, our previous data demonstrated that infiltrated monocytes/macrophages contribute to initiation of inflammation and development of EAM by promoting their polarization into M1-like phenotypes (8) that directly promote Th17 expansion or produce various proinflammatory cytokines, such as IL-1b, IL-6 and TNF-a (9-11). However, exact mechanism that drives monocyte/macrophage infiltration in EAM remains unclear.
Monocyte/macrophage infiltration is associated with chemokines and the chemokine receptor axis, which modulate the trafficking of immune cells to sites of inflammation or injury (12) . Published data indicate that ligation of chemokines with (CCR2/5 mediates emigration of monocytes/macrophages from the bone marrow, spleen or peripheral blood to the sites of injury (5, 13) . Additionally, CCR2 deficiency attenuates cardiac injury and similar impairments in monocyte migration have been identified in other inflammatory models (14) , such as autoimmune encephalitis (15) , atherosclerosis (16) and tuberculosis (17) . Which chemokine drives the monocyte/macrophage infiltration in EAM is thus far unclear.
Angiotensin II, a main mediator of the reninangiotensin system, plays critical roles in modulation of circulatory homeostasis and activation of innate and adaptive immunity. For example, ANG II can induce rapid neutrophil infiltration (18) , enhance the migration, maturation and antigen-presenting ability of DCs (19) and increase mononuclear cell accumulation through inducing nuclear factor-kB activity and MCP-1 expression (20) . Furthermore, ANG II has been implicated in several mouse models of autoimmune disease (21) . We have also noticed that inhibition of ANG II significantly decreases monocyte/macrophage infiltration in EAM, raising the question of whether ANG II directly drives monocyte/macrophage infiltration in EAM as a chemokine. Therefore, the present study aimed to address: (i) whether ANG II directly promotes monocyte/macrophage infiltration in EAM; and (ii) whether ANG II mediated monocyte/macrophage infiltration is associated with CCR2 or CCR5 or both. 
MATERIALS AND METHODS

Cells and mice
Induction of EAM
An EAM mouse model was created using our previous protocol (3) . Briefly, BALB/c mice were immunized with 100 mg of MyHC-a 614-629 (Ac-SLKLMATLFSTYASAD-OH), emulsified in a 1:1 ratio in PBS/complete Freund's adjuvant on Days 0 and 7. After 3 weeks, the mice were anaesthetized with pentobarbital sodium (30 mg/g body weight, i.p.), killed and their hearts rapidly excised .
CCR2/5 receptor antagonist treatment
CCR2 and CCR5 antagonists, RS 102895 hydrochloride (Sigma-Aldrich, Shanghai, China) and maraviroc (Selleck, Shanghai, China) were dissolved in sterile PBS and further diluted with DMSO. Mice were given 50 mg/kg RS 102895 hydrochloride i.p. or 10 mM maraviroc i.p. every three days until they were killed.
Histopathology
Heart tissues were fixed in 10% formalin and processed for standard HE staining. HE-stained sections were graded according to the Dallas criteria (22, 23) by two independent pathologists who were blinded to the group assigned in accordance with the following scale: 0, no or questionable presence of inflammatory cells; 1-2, limited focal distribution of inflammatory cells; 3, distribution of inflammatory cells greater than 10%; and 4, infiltration more than 30%. Sirius-red staining was used to evaluate cardiac fibrosis.
Quantitative RT-PCR (RT-qPCR)
Total RNA was isolated from the excised heart tissue using TRIzol reagent (Thermo Fisher Scientific, Shanghai, China) following the manufacturer's protocol and reverse transcribed into cDNA. IL-1b, TNF-a, IL-6, CCR2/5, collagen I/III (colI/III) and GAPDH were measured using a real-time PCR system (Bio-Rad, Hong Kong). Primer sequences are shown in Table 1 . Table 1 . Primer sequences used in this study
Transwell assay
Cell migration was performed using 24-well Transwell chambers with an 8 mm-pore-size polycarbonate filter (Costar, Cambridge, MA, USA) according to a previous description (24) . Briefly, ANA-1 cells were seeded in the upper chamber. The lower chamber was with/without CCR2/5 antagonists combined with ANG II. The cells were allowed to migrate for 12 hr, stained, and imaged. Images from five microscopic fields at the center of each well were counted.
Cytokine quantitation
ANG II was quantitated in serum or tissue suspension by using ELISA kits (MultiSciences (Lianke) Biotech, Hangzhou, China), according to the manufacturer's instructions.
Statistical analysis
Statistical analyses were performed using Graphpad Prism 5. Results are presented as means AE SD. Differences between two or multiple groups were compared by paired t-test or one-way anova with Bonferroni correction. P < 0.05 was considered to denote statistical significance.
RESULTS
ANG II expression is significantly upregulated in EAM
To explore the potential role of ANG II in EAM development, ANG II was quantitated in a mouse model of myocarditis. ANG II expression was significantly upregulated in serum (41.23 AE 3.31 pg/mL) compared with the control group (8.91 AE 1.37 pg/mL) (Fig. 1a) (P < 0.05). Additionally, at 116.53 AE 9.78 pg/mL ANG II was obviously up-regulated in heart tissues compared with the control group (46.23 AE 3.25 pg/mL) (Fig. 1b) (p < 0.05). Taken together, ANG II was up-regulated in both serum and heart tissues of EAM mice.
Losartan decreases monocyte/macrophage infiltration and ameliorates progression of EAM
To determine the chemotactic activity of ANG II for monocytes/macrophages in EAM mice, losartan, an ANG II receptor antagonist, was employed. Examination of HE-stained specimens showed that losartan treatment led to obvious decreases in necrosis of cardiac myocytes and monocyte/macrophage infiltration of the myocardium (Fig. 2a) . Scores for severity were significantly lower in the losartan-treated groups (E þ L; 1.12 AE 0.24) than in the EAM group (3.89 AE 0.31) (Fig. 2a) (P < 0.05). Expression of the inflammatory cytokines TNF-a, IL-b and IL-6 mRNA in heart tissues was clearly weaker in the E þ L group, being six-fold, 11-fold and 54-fold lower, respectively, than in the EAM group (Fig. 2b) . Furthermore, CCR2/5 mRNA expression was significantly lower in the E þ L than the EAM group (Fig. 2c) clearly lower in the antagonist-treated groups than in the EAM group (Fig. 3a) . Expression of the inflammatory cytokines TNF-a, IL-b and IL-6 mRNA in heart tissues was clearly down-regulated compared with the EAM group (Fig. 3b) . Furthermore, treatment with CCR2/5 receptor antagonists significantly reduced the percentage of sirius red-stained areas in mice with EAM (Fig. 3c) ; assessment of mRNA expression of colI/III confirmed this phenomenon (Fig. 3d) . Taken together, these results suggest that ANG II contribution to recruitment of monocytes/macrophages is partially dependent on the CCR2/5 axis and CCR2/5 blockade significantly ameliorates myocardial injury.
CCR2/5 antagonists abrogate ANG II chemotaxis of macrophage in vitro
ANA-1 macrophages were employed to further investigate ANG II chemotaxis for macrophages. As Figure 4 shows, ANG II significantly promoted migration of macrophages compared with the untreated group, but antagonists of CCR2 or CCR5 clearly reversed the ability of ANG II to induce macrophage migration. Taken together, these results further demonstrate that ANG II directly drives macrophage migration and that this is dependent on the CCR2/5 axis.
DISCUSSION
EAM is characterized by monocyte/macrophage infiltration, Th17 cell expansion, production of inflammatory factors and deterioration of cardiac function (25, 26) . Monocytes/macrophages are the important components of innate and adaptive immunity and play multiple roles in antigen presentation, immune defense and modulation, inflammation, tissue remodeling and autoimmune diseases (27, 28) such as experimental autoimmune encephalomyelitis (29) and experimental autoimmune uveitis (30) . Furthermore, macrophages , IL-1b, TNF-a mRNA expression in heart tissues. mRNA expression was quantitated using RT-qPCR. Gene expression was normalized with that of GAPDH. (c) CCR2, CCR5 mRNA expression in heart tissues was quantitated using RT-qPCR. Gene expression was normalized with that of GAPDH. Data are presented as means AE SD from five different mice. P < 0.05 by one-way anova with Bonferroni correction was considered to denote statistical significance.
are settled and reprogram towards M1 or M2 phenotypes in response to microenvironmental signals. Functional skewing of macrophages appears in physiological or pathological milieu, especially in inflammatory conditions. Phenotypic and functional changes in macrophage are considered important determinants of disease progression and/or regression (31, 32) . The present results demonstrate up-regulation of ANG II expression. The ANG II receptor antagonist, losartan, reduces monocyte/macrophage infiltration and Collagen I/III mRNA expression in the heart was quantitated using RT-qPCR. Gene expression was normalized with that of GAPDH. Results are presented as means AE SD from five different mice. P < 0.0 by one-way ANOVA with Bonferroni correction was considered to denote statistical significance.
Ã P < 0.05, ÃÃ P < 0.005,
attenuates cardiac injury; furthermore, following losartan treatment, mRNA expression of CCR2/5 is downregulated. CCR2/5 antagonists decrease myocarditis severity scores by preventing inflammatory monocyte/ macrophage infiltration and production of TNF-a, IL-6 and IL-1b. CCR2/5 antagonists also ameliorate cardiac fibrosis. All the data indicate that ANG II contributes to progression of EAM partially via CCR2/5-dependent monocyte/macrophage recruitment. Of course, other mechanisms may also be involved in ANG II-induced development of EAM. Published data indicate that ANG II regulates activation of DCs, which express both AT 1 R and AT 2 R. ANG II enhances the ability of DCs to migrate, mature and present antigens by ligation with AT 1 R (19, 33) . Furthermore, DCs have proinflammatory and cytotoxic activation properties and a strong capacity to induce Ag-specific (MyHC-a 614-629 ) T cell responses (34) . Additionally, some data suggest that ANG II acts as a costimulatory molecule for T cell activation, proliferation, differentiation and polarization. For example, the AT 1 R-ANG II axis induces increases in IFN-g and IL-17, suggesting that ANG II induces CD4 þ T cells to differentiate into Th1 or Th17 cells (35, 36) . Our data also indicate that ANG II contributes to skewing of macrophage functions (unpublished data). Therefore, we speculate that ANG II is involved in T cell-mediated development of EAM by regulating DC activation, promoting Th17 cell expansion and contributing to macrophage recruitment and skewing of function.
In conclusion, ANG II contribution to development of EAM is partially dependent on monocyte/macrophage recruitment through the CCR2/5 axis and ANG II is a potential chemokine for monocytes/macrophages. Furthermore, our data indicate that ANG II is a potential candidate for treatment of inflammatory diseases. The Transwell plates were then incubated for 12 hr at 37°C in a 5% CO 2 humidified atmosphere. All data are presented as means AE SD from three independent experiments. P < 0.05 by one-way ANOVA with Bonferroni correction was considered to denote statistical significance. ÃÃ P < 0.005. C, control; A, ANG II;
A þ C2, ANG II þ CCR2 antagonists; A þ C5, ANG II þ CCR5 antagonists.
